United States · Abortion · 2023–2024
The abortion-drug dispute that turned on standing
A Fifth Circuit ruling on FDA regulation reached a unanimous Supreme Court reversal on the threshold question of who could sue.
Public historical research, separate from your private cases. Each collection ends at the dates shown. Summaries describe the judgments at that time; they are not a current-law citator or an eligibility assessment. Editorial notes are in English.
The competing arguments
Can a court decide an emotionally charged dispute before the plaintiffs establish a concrete injury?
The challengers’ theory
The doctors and associations argued that FDA decisions could cause conscience injuries, divert medical resources and harm their members.
The jurisdictional response
FDA and Danco disputed standing and defended the regulatory actions. The Supreme Court resolved standing without reaching the administrative-law merits.
How the decisions connect
Editorial reading guide. Each connection links to the judgments and explains the kind of disagreement.
Reversed on standing
FDA v. Alliance for Hippocratic Medicinerelates toAlliance for Hippocratic Medicine v. FDA
The Supreme Court rejected the plaintiffs’ entitlement to sue rather than deciding the drug-regulation merits.
The decision timeline
· US Court of Appeals, Fifth Circuit
Alliance for Hippocratic Medicine v. FDA
78 F.4th 210 · Panel decision; Ho concurred in part and dissented in part
Could these plaintiffs challenge FDA actions, and should interim relief against those actions stand?
- What the court decided
- The panel accepted standing for challenges to the 2016 and 2021 actions and upheld interim relief as to those actions, while rejecting other parts of the district court’s order.
- Where the disagreement sits
- The panel’s treatment of the claimed injuries became decisive on review. Its opinion expressly acknowledged the Supreme Court stay; the panel’s restrictions did not simply take immediate effect.
- Historical treatment and limits
- Reversed by the Supreme Court in 2024 for lack of Article III standing.
Read the source and pinpoint
Judgment · 78 F.4th 210Opinion pp. 2–4, standing section; separate Ho opinion
· US Supreme Court
FDA v. Alliance for Hippocratic Medicine
602 U.S. 367 · Unanimous; Thomas also concurred
Had the associations and doctors shown an injury traceable to FDA’s actions that a court could redress?
- What the court decided
- The Court held that these plaintiffs lacked Article III standing and reversed. Their asserted conscience, economic and organizational injuries did not establish the required connection to FDA’s actions.
- Where the disagreement sits
- A unanimous procedural outcome did not decide whether FDA’s decisions were lawful on the merits. Thomas’s concurrence separately questioned associational-standing doctrine.
- Historical treatment and limits
- Historical endpoint: June 2024. This was not a ruling guaranteeing access everywhere or foreclosing every later challenge.
Questions worth investigating
- What is the difference between disagreeing with government policy and suffering an Article III injury?
- How did the existing stay affect the practical meaning of the Fifth Circuit’s ruling?
- What issues did the Supreme Court leave undecided?
Sources reviewed 2026-11-08. Holdings and separate opinions are summarized in our own words.